X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Abbott India with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs GSK PHARMA - Comparison Results

ABBOTT INDIA    Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA GSK PHARMA ABBOTT INDIA/
GSK PHARMA
 
P/E (TTM) x 39.4 67.4 58.4% View Chart
P/BV x 11.4 11.8 96.3% View Chart
Dividend Yield % 0.5 1.1 50.3%  

Financials

 ABBOTT INDIA   GSK PHARMA
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-17
GSK PHARMA
Mar-17
ABBOTT INDIA/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs5,1903,838 135.2%   
Low Rs4,3512,637 165.0%   
Sales per share (Unadj.) Rs1,382.9354.2 390.4%  
Earnings per share (Unadj.) Rs130.239.8 327.4%  
Cash flow per share (Unadj.) Rs137.942.9 321.7%  
Dividends per share (Unadj.) Rs40.0030.00 133.3%  
Dividend yield (eoy) %0.80.9 90.5%  
Book value per share (Unadj.) Rs652.7236.9 275.5%  
Shares outstanding (eoy) m21.2584.70 25.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.49.1 37.7%   
Avg P/E ratio x36.681.4 45.0%  
P/CF ratio (eoy) x34.675.5 45.8%  
Price / Book Value ratio x7.313.7 53.5%  
Dividend payout %30.775.4 40.7%   
Avg Mkt Cap Rs m101,373274,216 37.0%   
No. of employees `0003.14.7 65.6%   
Total wages/salary Rs m3,4534,830 71.5%   
Avg. sales/employee Rs Th9,531.96,387.0 149.2%   
Avg. wages/employee Rs Th1,119.91,028.3 108.9%   
Avg. net profit/employee Rs Th897.3717.1 125.1%   
INCOME DATA
Net Sales Rs m29,38730,000 98.0%  
Other income Rs m576728 79.2%   
Total revenues Rs m29,96330,728 97.5%   
Gross profit Rs m3,9734,190 94.8%  
Depreciation Rs m164263 62.5%   
Interest Rs m200-   
Profit before tax Rs m4,3654,655 93.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0457 0.0%   
Tax Rs m1,5981,744 91.7%   
Profit after tax Rs m2,7673,368 82.1%  
Gross profit margin %13.514.0 96.8%  
Effective tax rate %36.637.5 97.7%   
Net profit margin %9.411.2 83.9%  
BALANCE SHEET DATA
Current assets Rs m18,90616,742 112.9%   
Current liabilities Rs m6,2977,202 87.4%   
Net working cap to sales %42.931.8 134.9%  
Current ratio x3.02.3 129.2%  
Inventory Days Days6252 120.0%  
Debtors Days Days2221 104.1%  
Net fixed assets Rs m1,1598,635 13.4%   
Share capital Rs m213847 25.1%   
"Free" reserves Rs m13,65719,222 71.1%   
Net worth Rs m13,86920,069 69.1%   
Long term debt Rs m010 0.0%   
Total assets Rs m20,63830,038 68.7%  
Interest coverage x215.0NM-  
Debt to equity ratio x00 0.0%  
Sales to assets ratio x1.41.0 142.6%   
Return on assets %13.511.2 120.4%  
Return on equity %19.916.8 118.9%  
Return on capital %31.625.5 124.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m0528 0.0%   
Fx outflow Rs m07,193 0.0%   
Net fx Rs m0-6,665 0.0%   
CASH FLOW
From Operations Rs m3,0722,360 130.2%  
From Investments Rs m-1,5543,008 -51.7%  
From Financial Activity Rs m-898-5,108 17.6%  
Net Cashflow Rs m621260 238.4%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 75.0 50.7 147.9%  
Indian inst/Mut Fund % 7.9 10.2 77.5%  
FIIs % 0.1 23.8 0.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.1 15.4 111.0%  
Shareholders   18,270 102,036 17.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   JUBILANT LIFE SCIENCES  DR. DATSONS LABS  CADILA HEALTHCARE  SANOFI INDIA  PANACEA BIOTECH  

Compare ABBOTT INDIA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Day up 260 Points; Pharma Stocks Top Gainers(Closing)

After opening the day in red, share markets in India witnessed positive trading activity throughout the day and ended the day on a positive note.

Related Views on News

ABBOTT INDIA at All Time High; BSE HEALTHCARE Index Down 0.7%

Jun 22, 2018 | Updated on Jun 22, 2018

ABBOTT INDIA share price has hit an all time high at Rs 7,420 (up 1.67%). The BSE HEALTHCARE Index is down by 0.74%. Among the top gainers in the BSE HEALTHCARE Index today are ABBOTT INDIA (up 1.67%) and GSK PHARMA (up 0.01%). The top losers include PFIZER (down 0.00%) and IPCA LABS (down 0.01%).

GSK PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 6.4%

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, GSK PHARMA has posted a net profit of Rs 1 bn (down 6.4% YoY). Sales on the other hand came in at Rs 7 bn (down 4.5% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

Will You Dump Your Client if You're Busy? Inox Wind's Auditor Just Did...(The 5 Minute Wrapup)

Jun 14, 2018

After Inox Wind, you may see more auditors resigning And the reasons can be as funny as they can get.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Should You Invest In Mirae Asset Healthcare Fund?(Outside View)

Jun 15, 2018

Mirae Asset Mutual Fund launches NFO - Mirae Asset Helathcare Fund.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Jun 22, 2018 (Close)

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA - LUPIN LTD COMPARISON

COMPARE ABBOTT INDIA WITH

MARKET STATS